KD 295
Alternative Names: Cell culture based H5N1 vaccine - GSK; Emulsion Cell Culture Influenza HA Vaccine (Prototype); Flu pandemic - GSK; KD-295Latest Information Update: 02 Aug 2023
At a glance
- Originator GlaxoSmithKline; Kaketsuken
- Developer GSK; Japan Vaccine
- Class Influenza A virus H5N1 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Influenza A virus H5N1 subtype
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Influenza-A-virus-H5N1-subtype(Prevention) in Austria (IM, Injection)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Influenza-A-virus-H5N1-subtype(Prevention) in Belgium (IM, Injection)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Influenza-A-virus-H5N1-subtype(Prevention) in United Kingdom (IM, Injection)